Free Trial

Biomerica (BMRA) Competitors

Biomerica logo
$3.27 -0.13 (-3.82%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$3.36 +0.09 (+2.75%)
As of 08:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BMRA vs. ESLA, BDRX, RANI, EYEN, MRNS, DYAI, KALA, ALLK, MAAQ, and ENLV

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Estrella Immunopharma (ESLA), Biodexa Pharmaceuticals (BDRX), Rani Therapeutics (RANI), Eyenovia (EYEN), Marinus Pharmaceuticals (MRNS), Dyadic International (DYAI), KALA BIO (KALA), Allakos (ALLK), Mana Capital Acquisition (MAAQ), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry.

Biomerica vs. Its Competitors

Estrella Immunopharma (NASDAQ:ESLA) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Biomerica has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.35
Biomerica$5.68M1.47-$5.98M-$2.32-1.41

Estrella Immunopharma has a net margin of 0.00% compared to Biomerica's net margin of -85.42%. Biomerica's return on equity of -85.90% beat Estrella Immunopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A -1,132.38% -273.91%
Biomerica -85.42%-85.90%-61.06%

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 15.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Biomerica had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Biomerica and 0 mentions for Estrella Immunopharma. Biomerica's average media sentiment score of 0.65 beat Estrella Immunopharma's score of 0.00 indicating that Biomerica is being referred to more favorably in the news media.

Company Overall Sentiment
Estrella Immunopharma Neutral
Biomerica Positive

Estrella Immunopharma has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.

Estrella Immunopharma currently has a consensus target price of $16.00, suggesting a potential upside of 1,736.13%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Estrella Immunopharma is more favorable than Biomerica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Estrella Immunopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Biomerica
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Biomerica beats Estrella Immunopharma on 8 of the 15 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRA vs. The Competition

MetricBiomericaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.32M$2.68B$5.50B$8.94B
Dividend YieldN/A1.79%5.25%4.04%
P/E Ratio-1.418.9826.9720.11
Price / Sales1.47714.59426.02119.76
Price / CashN/A159.8036.8257.86
Price / Book1.044.517.985.56
Net Income-$5.98M$31.26M$3.16B$248.40M
7 Day Performance1.24%3.57%2.36%4.67%
1 Month Performance-4.39%1.28%2.15%6.64%
1 Year Performance-4.54%1.08%33.78%21.31%

Biomerica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRA
Biomerica
0.3801 of 5 stars
$3.27
-3.8%
N/A-7.4%$8.32M$5.68M-1.4160
ESLA
Estrella Immunopharma
2.2166 of 5 stars
$0.96
+9.0%
$16.00
+1,566.7%
-29.7%$31.86MN/A-3.69N/APositive News
BDRX
Biodexa Pharmaceuticals
N/A$0.87
-0.6%
N/AN/A$31.79M$470K0.0020Upcoming Earnings
RANI
Rani Therapeutics
1.4906 of 5 stars
$0.51
-6.9%
$7.33
+1,327.0%
-83.3%$31.73M$1.03M-0.52110News Coverage
EYEN
Eyenovia
1.0008 of 5 stars
$10.38
-4.6%
$2.00
-80.7%
-77.3%$31.36M$60K-0.1840High Trading Volume
MRNS
Marinus Pharmaceuticals
2.3257 of 5 stars
$0.55
-0.2%
$3.92
+613.3%
-54.2%$30.32M$30.99M-0.22110
DYAI
Dyadic International
1.9966 of 5 stars
$0.99
-0.9%
$6.00
+506.1%
-33.4%$30.06M$3.49M-4.957Gap Down
KALA
KALA BIO
3.469 of 5 stars
$4.76
+3.0%
$13.50
+183.6%
-24.2%$29.81M$3.89M-0.5830News Coverage
ALLK
Allakos
3.0262 of 5 stars
$0.33
flat
$2.00
+507.7%
N/A$29.74MN/A-0.16190
MAAQ
Mana Capital Acquisition
N/A$3.61
+9.4%
N/A-36.7%$29.33MN/A0.001High Trading Volume
ENLV
Enlivex Therapeutics
3.1655 of 5 stars
$1.12
-6.7%
$10.00
+792.9%
-11.9%$28.38MN/A-1.7070Positive News

Related Companies and Tools


This page (NASDAQ:BMRA) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners